These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30906662)

  • 1. Correlation between patients' age and cancer immunotherapy efficacy.
    Wu Q; Wang Q; Tang X; Xu R; Zhang L; Chen X; Xue Q; Wang Z; Shi R; Wang F; Ju F; Zhang B; Zhou YL
    Oncoimmunology; 2019; 8(4):e1568810. PubMed ID: 30906662
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
    Nishijima TF; Muss HB; Shachar SS; Moschos SJ
    Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
    J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yan X; Tian X; Wu Z; Han W
    Front Oncol; 2020; 10():1671. PubMed ID: 33072551
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.
    Kim CM; Lee JB; Shin SJ; Ahn JB; Lee M; Kim HS
    ESMO Open; 2022 Oct; 7(5):100577. PubMed ID: 36156450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
    JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis.
    Li P; Yang X; Feng Y; Wu L; Ma W; Ding G; Wei Y; Sun L
    Onco Targets Ther; 2018; 11():7521-7527. PubMed ID: 30464500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
    J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.
    Kim BJ; Kim JH; Kim HS
    Oncotarget; 2017 Aug; 8(31):51779-51785. PubMed ID: 28881686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
    Wang S; Hao J; Wang H; Fang Y; Tan L
    Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
    Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
    Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis.
    Huang L; Chen X; Zhou L; Xu Q; Xie J; Zhan P; Lv T; Song Y
    Ann Palliat Med; 2021 Mar; 10(3):2709-2722. PubMed ID: 33549013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Chen DL; Li QY; Tan QY
    J Thorac Dis; 2021 Jan; 13(1):220-231. PubMed ID: 33569202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer.
    Wang Z; Zhang B; Zhang C; Ren S; Wang W; Wang Y; Jiang T; Wei H; Li Y; Wu Q; Chen J
    Int Immunopharmacol; 2019 Sep; 74():105709. PubMed ID: 31276976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.